Indications for Ordering CEA
CEA should be ordered in three specific clinical scenarios for colorectal cancer: (1) preoperatively to assist with staging and surgical planning, (2) postoperatively every 3 months for at least 3 years in stage II or III disease patients who are candidates for surgery or systemic therapy, and (3) at baseline and every 1-3 months during active treatment for metastatic disease to monitor response to therapy. 1
When NOT to Order CEA
CEA is not recommended as a screening test for colorectal cancer due to very low sensitivity for detecting occult cancers, despite high specificity 1. Do not use CEA for population screening or initial cancer detection.
Specific Clinical Indications
1. Preoperative Staging and Surgical Planning
- Order CEA preoperatively in patients with confirmed colorectal carcinoma if it will assist in staging and surgical treatment planning 1
- Elevated preoperative CEA (≥5 mg/mL) correlates with poorer prognosis 1
- Important caveat: Data are insufficient to use CEA alone to determine whether to treat with adjuvant therapy 1
- Preoperative CEA is particularly valuable in patients being considered for resection of liver or pulmonary metastases, as it provides prognostic information 1
2. Postoperative Surveillance
Perform postoperative serum CEA testing every 3 months in patients with stage II or III disease for at least 3 years after diagnosis, but only if the patient is a candidate for surgery or systemic therapy 1
Critical timing consideration: Wait until chemotherapy is finished before initiating CEA surveillance, as chemotherapy may falsely elevate CEA levels 1
When CEA is elevated during surveillance:
- Confirm by retesting
- An elevated CEA warrants further evaluation for metastatic disease
- Do not initiate systemic therapy based on elevated CEA alone without radiographic confirmation 1, 2
3. Monitoring Response to Therapy in Metastatic Disease
CEA is the marker of choice for monitoring metastatic colorectal cancer during systemic therapy 1, 2
Specific protocol:
- Measure CEA at the start of treatment for metastatic disease
- Repeat every 1-3 months during active treatment 1
- Persistently rising values above baseline should prompt restaging
- Rising CEA suggests progressive disease even without corroborating radiographs 1
Important pitfall: Exercise caution when interpreting a rising CEA level during the first 4-6 weeks of new therapy, as spurious early rises may occur, especially after oxaliplatin 1
Key Clinical Caveats
- Smoking history matters: CEA levels can be elevated in smokers without malignancy 3
- Inflammatory conditions: CEA may be elevated in inflammatory diseases of the bowel, lung, pancreas, and other organs 3
- Laboratory variability: Measured CEA levels may differ between laboratories and countries 1
- Sensitivity limitations: CEA is most sensitive for detecting liver metastases (approximately 80% sensitivity), but less sensitive for locoregional or pulmonary metastases 4, 5
What CEA Cannot Do
- Cannot replace standard diagnostic methods for cancer detection 3
- Should not be used to determine adjuvant therapy decisions 1
- An elevated CEA alone does not justify systemic therapy for presumed metastatic disease 1, 2
- Not useful for screening, diagnosis, or determining prognosis in early-stage disease for treatment planning 1